Endowment Wealth Management’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.1K Hold
11,521
– – 0.01% 181
2026
Q1
$19.5K Hold
11,521
– – 0.01% 165
2025
Q4
$16.4K Buy
+11,521
New +$16.8K 0.01% 151

Other funds holding CHRS

Endowment Wealth Management's CHRS Position: Q2 2026 in Review

Endowment Wealth Management held its Coherus Oncology (CHRS) position steady in Q2 2026 at 11,521 shares worth $16.1K. The position accounts for 0.01% of the portfolio, ranked #181.

Endowment Wealth Management first reported a position in CHRS in Q4 2025 and has held it in 3 quarters since. The position peaked at $19.5K in Q1 2026. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Endowment Wealth Management held 11,521 shares of Coherus Oncology worth $16.1K as of Q2 2026.
  • Endowment Wealth Management left its Coherus Oncology share count unchanged in Q2 2026.
  • Coherus Oncology made up 0.01% of Endowment Wealth Management's portfolio in Q2 2026, its #181 holding.
  • Endowment Wealth Management first reported a position in Coherus Oncology in Q4 2025 and has held it in 3 quarters since.
  • Endowment Wealth Management's Coherus Oncology position peaked at $19.5K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Endowment Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.